IFN-beta in CIS: phase III REFLEX results


The higher dose of interferon-beta-1a (Rebif; 44 mcg) appears to effective in patients with clinically isolated syndrome (CIS) suggestive of MS, according to the results of the phase III REFLEX trial (Comi et al. Lancet Neurol 2012;11:33-41).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page